VIZIMPRO
Drug
PFIZER INC.
Total Payments
$11.7M
Transactions
205
Doctors
69
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $224,409 | 2 | 0 |
| 2023 | $324,046 | 5 | 4 |
| 2022 | $1.2M | 9 | 1 |
| 2021 | $1.1M | 6 | 0 |
| 2020 | $4.5M | 24 | 0 |
| 2019 | $3.0M | 101 | 42 |
| 2018 | $1.4M | 58 | 24 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11.6M | 128 | 99.7% |
| Consulting Fee | $17,500 | 5 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,780 | 4 | 0.1% |
| Travel and Lodging | $6,544 | 11 | 0.1% |
| Education | $579.27 | 40 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $500.00 | 1 | 0.0% |
| Food and Beverage | $202.65 | 16 | 0.0% |
Payments by Type
Research
$11.6M
128 transactions
General
$32,106
77 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PHASE 1 STUDY OF COMBINATION DACOMITINIB AND OSIMERTINIB FOR PATIENTS WITH METASTATIC EGFR MUTANT LUNG CANCERS | PFIZER INC. | $7.9M | 0 |
| A PHASE 2 STUDY OF DACOMITINIB AFTER DISEASE PROGRESSION ON FIRSTLINE OSIMERTINIB IN PATIENTS WITH EGFRMUTANT LUNG CANCERS | PFIZER INC. | $3.1M | 0 |
| A PHASE 1 STUDY TO EVALUATE THE SINGLE DOSE PHARMACOKINETICS OF DACOMITINIB PF00299804 IN SUBJECTS WITH IMPAIRED HEPATIC FUNCTION | PFIZER INC. | $373,818 | 0 |
| ARCHER 1042 A PHASE 2 STUDY OF DACOMITINIB IN ADVANCED NONSMALL CELL LUNG CANCER POSTCHEMOTHERAPY OR SELECT FIRST LINE PATIENTS TO EVALUATE PROPHYLACTIC INTERVENTION ON DERMATOLOGIC AND GASTROINTESTINAL ADVERSE EVENTS AND PATIENT REPORTED OUTCOMES | PFIZER INC. | $133,144 | 0 |
| AN OPENLABEL PHASE 2 TRIAL OF ORALLY ADMINISTERED PF00299804 IN ADULT PATIENTS WITH RELAPSED RECURRENT GLIOBLASTOMA GBM | PFIZER INTERNATIONAL LLC | $73,643 | 0 |
| ARCHER 1009A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF PF00299804 DACOMITINIB VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NONSMALL CELL LUNG CANCER FOLLOWING PROGRESSION AFTER OR INTOLERANCE TO AT LEAST ONE PRIOR CHEMOTHERAPY | PFIZER INC. | $14,781 | 0 |
| DACOMITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $12,800 | 4 |
| PHASE 2 OPEN LABEL TRIAL OF ORAL INTERMITTENT DACOMITINIB IN PATIENTS WITH ADVANCED NSCLC | PFIZER INC. | $8,450 | 0 |
Top Doctors Receiving Payments for VIZIMPRO — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Hematology & Oncology | Elgin, IL | $15.32 | 1 |
| , M.D | Hematology & Oncology | Long Beach, CA | $15.32 | 1 |
| , M.D | Hematology & Oncology | Kamuela, HI | $15.32 | 1 |
| , M.D | Medical Oncology | Honolulu, HI | $15.32 | 1 |
| , M.D | Hematology & Oncology | Honolulu, HI | $15.32 | 1 |
| , M.D | Hematology & Oncology | Honolulu, HI | $15.32 | 1 |
| , M.D | Hematology & Oncology | Whittier, CA | $15.32 | 1 |
| , MD | Medical Oncology | Bolivar, MO | $15.32 | 1 |
| , M.D | Hematology & Oncology | Merrillville, IN | $15.32 | 1 |
| , MD | Hematology & Oncology | Columbia, MO | $15.32 | 1 |
| , MD | Hematology & Oncology | Kaneohe, HI | $15.32 | 1 |
| , MD | Hematology | Aiea, HI | $15.32 | 1 |
| , MD | Hematology & Oncology | Kamuela, HI | $15.32 | 1 |
| , M.D | Hematology & Oncology | Honolulu, HI | $15.32 | 1 |
| , D.O | Hematology & Oncology | Grove, OK | $15.32 | 1 |
| Charles Morgan | Medical Oncology | West Plains, MO | $15.32 | 1 |
| , MD | Hematology & Oncology | Rolla, MO | $15.32 | 1 |
| , M.D | Hematology & Oncology | Aiea, HI | $15.32 | 1 |
| , MD | Internal Medicine | Columbia, MO | $15.32 | 1 |
| , M.D | Hematology & Oncology | Rolla, MO | $15.32 | 1 |
| , M.D | Medical Oncology | Columbia, MO | $15.32 | 1 |
| , M.D | Hematology & Oncology | Aiea, HI | $15.32 | 1 |
| , M.D | Internal Medicine | Honolulu, HI | $15.32 | 1 |
| Clayton Chong | — | Honolulu, HI | $15.32 | 1 |
| , M.D | Hematology & Oncology | Wailuku, HI | $15.32 | 1 |
Ad
Manufacturing Companies
- PFIZER INC. $11.6M
- PFIZER INTERNATIONAL LLC $73,643
- PFIZER PHARMACEUTICALS LLC $2.78
Product Information
- Type Drug
- Total Payments $11.7M
- Total Doctors 69
- Transactions 205
About VIZIMPRO
VIZIMPRO is a drug associated with $11.7M in payments to 69 healthcare providers, recorded across 205 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2018 to 2024. In 2024, $224,409 was paid across 2 transactions to 0 doctors.
The most common payment nature for VIZIMPRO is "Unspecified" ($11.6M, 99.7% of total).
VIZIMPRO is associated with 8 research studies, including "PHASE 1 STUDY OF COMBINATION DACOMITINIB AND OSIMERTINIB FOR PATIENTS WITH METASTATIC EGFR MUTANT LUNG CANCERS" ($7.9M).